13 research outputs found
Early mobilisation in critically ill COVID-19 patients: a subanalysis of the ESICM-initiated UNITE-COVID observational study
Background
Early mobilisation (EM) is an intervention that may improve the outcome of critically ill patients. There is limited data on EM in COVID-19 patients and its use during the first pandemic wave.
Methods
This is a pre-planned subanalysis of the ESICM UNITE-COVID, an international multicenter observational study involving critically ill COVID-19 patients in the ICU between February 15th and May 15th, 2020. We analysed variables associated with the initiation of EM (within 72 h of ICU admission) and explored the impact of EM on mortality, ICU and hospital length of stay, as well as discharge location. Statistical analyses were done using (generalised) linear mixed-effect models and ANOVAs.
Results
Mobilisation data from 4190 patients from 280 ICUs in 45 countries were analysed. 1114 (26.6%) of these patients received mobilisation within 72 h after ICU admission; 3076 (73.4%) did not. In our analysis of factors associated with EM, mechanical ventilation at admission (OR 0.29; 95% CI 0.25, 0.35; p = 0.001), higher age (OR 0.99; 95% CI 0.98, 1.00; p ≤ 0.001), pre-existing asthma (OR 0.84; 95% CI 0.73, 0.98; p = 0.028), and pre-existing kidney disease (OR 0.84; 95% CI 0.71, 0.99; p = 0.036) were negatively associated with the initiation of EM. EM was associated with a higher chance of being discharged home (OR 1.31; 95% CI 1.08, 1.58; p = 0.007) but was not associated with length of stay in ICU (adj. difference 0.91 days; 95% CI − 0.47, 1.37, p = 0.34) and hospital (adj. difference 1.4 days; 95% CI − 0.62, 2.35, p = 0.24) or mortality (OR 0.88; 95% CI 0.7, 1.09, p = 0.24) when adjusted for covariates.
Conclusions
Our findings demonstrate that a quarter of COVID-19 patients received EM. There was no association found between EM in COVID-19 patients' ICU and hospital length of stay or mortality. However, EM in COVID-19 patients was associated with increased odds of being discharged home rather than to a care facility.
Trial registration ClinicalTrials.gov: NCT04836065 (retrospectively registered April 8th 2021)
Circulating leptin, soluble leptin receptor and free leptin index in critically ill patients with sepsis: a prospective observational study
BACKGROUND: Leptin, the prototype adipokine, exerts immunomodulatory
actions being implicated in inflammatory responses during sepsis.
Clinical evidence regarding its role in sepsis has been contradictory,
while free leptin has not been studied. The aim of this study was to
jointly investigate circulating total leptin, its soluble receptor
(sOB-R), and free leptin, as well as their kinetics in critically ill
patients with sepsis regarding their diagnostic and prognostic value.
METHODS: In a prospective study, serum total leptin, sOB-R and free
leptin index (FLI) were determined in 102 critically ill patients with
sepsis within 48 hours from sepsis onset and one week after enrollment,
and in 102 age and gender-matched healthy controls.
RESULTS: Upon enrolment, total leptin, sOB-R and FLI were significantly
higher in septic patients compared to controls and they were positively
correlated with sepsis severity scores, while they presented a
significant decrease during the first week (P<0.001). The decrease in
total leptin and sOB-R was significantly higher in patients with sepsis
compared to septic shock and in survivors compared to non-survivors at
28 days (P<0.001). Higher serum total leptin was independently
associated with survival at 28 days (enrollment: HR 0.86, P=0.03; one
week after: HR 0.77, P<0.001). Higher kinetics of total leptin (but not
FLI) was independently associated with survival after adjustment (HR:
0.48, P=0.001).
CONCLUSIONS: Higher circulating total leptin and its higher kinetics
during the first week from sepsis onset independently predict 28-day
survival in critically ill patients. Free leptin did not present any
additional diagnostic and prognostic value in sepsis
Circulating Chemerin and Its Kinetics May Be a Useful Diagnostic and Prognostic Biomarker in Critically Ill Patients with Sepsis: A Prospective Study
Chemerin, a novel adipokine, is a potent chemoattractant molecule with antimicrobial properties, implicated in immune responses. Our aim was to investigate circulating chemerin and its kinetics, early in sepsis in critically ill patients and its association with severity and prognosis. Serum chemerin was determined in a cohort of 102 critically ill patients with sepsis during the first 48 h from sepsis onset and one week later, and in 102 age- and gender-matched healthy controls. Patients were followed for 28 days and their outcomes were recorded. Circulating chemerin was significantly higher in septic patients at onset compared to controls (342.3 ± 108.1 vs. 200.8 ± 40.1 μg/L, p < 0.001). Chemerin decreased significantly from sepsis onset to one week later (342.3 ± 108.1 vs. 308.2 ± 108.5 μg/L, p < 0.001), but remained higher than in controls. Chemerin was higher in patients presenting with septic shock than those with sepsis (sepsis onset: 403.2 ± 89.9 vs. 299.7 ± 99.5 μg/L, p < 0.001; one week after: 374.9 ± 95.3 vs. 261.6 ± 91.9 μg/L, p < 0.001), and in nonsurvivors than survivors (sepsis onset: 427.2 ± 96.7 vs. 306.9 ± 92.1 μg/L, p < 0.001; one week after: 414.1 ± 94.5 vs. 264.2 ± 79.9 μg/L, p < 0.001). Moreover, patients with septic shock and nonsurvivors, presented a significantly lower absolute and relative decrease in chemerin one week after sepsis onset compared to baseline (p < 0.001). Based on ROC curve analyses, the diagnostic performance of chemerin (AUC 0.78, 95% CI 0.69–0.87) was similar to C-reactive protein (CRP) (AUC 0.78, 95% CI 0.68–0.87) in discriminating sepsis severity. However, increased chemerin at sepsis onset and one week later was an independent predictor of 28-day mortality (sepsis onset: HR 3.58, 95% CI 1.48–8.65, p = 0.005; one week after: HR 10.01, 95% CI 4.32–23.20, p < 0.001). Finally, serum chemerin exhibited significant correlations with the severity scores, white blood cells, lactate, CRP and procalcitonin, as well as with biomarkers of glucose homeostasis, but not with cytokines and soluble urokinase-type plasminogen activator receptor (suPAR). Circulating chemerin is increased early in sepsis and its kinetics may have diagnostic and prognostic value in critically ill patients. Further studies are needed to shed light on the role of chemerin in sepsis
Circulating Chemerin and Its Kinetics May Be a Useful Diagnostic and Prognostic Biomarker in Critically Ill Patients with Sepsis: A Prospective Study
Chemerin, a novel adipokine, is a potent chemoattractant molecule with
antimicrobial properties, implicated in immune responses. Our aim was to
investigate circulating chemerin and its kinetics, early in sepsis in
critically ill patients and its association with severity and prognosis.
Serum chemerin was determined in a cohort of 102 critically ill patients
with sepsis during the first 48 h from sepsis onset and one week later,
and in 102 age- and gender-matched healthy controls. Patients were
followed for 28 days and their outcomes were recorded. Circulating
chemerin was significantly higher in septic patients at onset compared
to controls (342.3 +/- 108.1 vs. 200.8 +/- 40.1 mu g/L, p < 0.001).
Chemerin decreased significantly from sepsis onset to one week later
(342.3 +/- 108.1 vs. 308.2 +/- 108.5 mu g/L, p < 0.001), but remained
higher than in controls. Chemerin was higher in patients presenting with
septic shock than those with sepsis (sepsis onset: 403.2 +/- 89.9 vs.
299.7 +/- 99.5 mu g/L, p < 0.001; one week after: 374.9 +/- 95.3 vs.
261.6 +/- 91.9 mu g/L, p < 0.001), and in nonsurvivors than survivors
(sepsis onset: 427.2 +/- 96.7 vs. 306.9 +/- 92.1 mu g/L, p < 0.001; one
week after: 414.1 +/- 94.5 vs. 264.2 +/- 79.9 mu g/L, p < 0.001).
Moreover, patients with septic shock and nonsurvivors, presented a
significantly lower absolute and relative decrease in chemerin one week
after sepsis onset compared to baseline (p < 0.001). Based on ROC curve
analyses, the diagnostic performance of chemerin (AUC 0.78, 95% CI
0.69-0.87) was similar to C-reactive protein (CRP) (AUC 0.78, 95% CI
0.68-0.87) in discriminating sepsis severity. However, increased
chemerin at sepsis onset and one week later was an independent predictor
of 28-day mortality (sepsis onset: HR 3.58, 95% CI 1.48-8.65, p =
0.005; one week after: HR 10.01, 95% CI 4.32-23.20, p < 0.001).
Finally, serum chemerin exhibited significant correlations with the
severity scores, white blood cells, lactate, CRP and procalcitonin, as
well as with biomarkers of glucose homeostasis, but not with cytokines
and soluble urokinase-type plasminogen activator receptor (suPAR).
Circulating chemerin is increased early in sepsis and its kinetics may
have diagnostic and prognostic value in critically ill patients. Further
studies are needed to shed light on the role of chemerin in sepsis